Incretin Atlas › Trials › REDEFINE 2
REDEFINE 2
CagriSema · t2d
Design
- Molecule(s)
- CagriSema
- Population
- t2d
- Official title
- A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
- Sponsor
- Novo Nordisk A/S
- Phase
- 3
- Registry status
- completed · 2023-02 → 2025-01
- Participants
- 1206
- Duration
- 68 weeks
- Registry
- NCT05394519
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CagriSema 2.4/2.4 mg | t2d | 68 | 1206 | −15.7 % vs −3.1 % Δ −12.6 pp | −13.7 % vs −3.4 % Δ −10.3 pp | −1.8 vs −0.4 | 8.4 vs 3.0 | — | — | — | 10.4 vs 12.9 | −6.5 vs −2.4 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- CagriSema 2.4/2.4 mg: Nausea, vomiting and per-arm discontinuation are in the supplementary appendix only.
Verbatim quotes from the source (6)
- CagriSema 2.4/2.4 mg · weight_tp · Results, Body Weight (p.652); also Table 2 row 'Percent chan
For the treatment-policy estimand, the estimated mean change in body weight from baseline to week 68 (the first primary end point) was –13.7% with cagrilintide–semaglutide, as compared with –3.4% with placebo (estimated
- CagriSema 2.4/2.4 mg · weight_eff · Results, Body Weight (p.652); Fig. 1B; full table in Table S
For the trial-product estimand, the change in body weight was –15.7% with cagrilintide–semaglu- tide and –3.1% with placebo (estimated differ- ence, –12.6 percentage points; 95% CI, –13.4 to –11.7)
- CagriSema 2.4/2.4 mg · hba1c · Results, Glycemic-Related End Points (p.654); Table 2 row 'C
For the treatment-policy estimand, cagrilintide– semaglutide led to a greater mean reduction in the glycated hemoglobin level from baseline to week 68, as compared with placebo (–1.8 per- centage points vs. –0.4 percenta
- CagriSema 2.4/2.4 mg · sbp · Table 2 (p.652), confirmatory secondary end point; also Resu
Change in systolic blood pressure — mm Hg –6.5 –2.4 –4.1 (–6.0 to –2.1)
- CagriSema 2.4/2.4 mg · ae_dc · Table 3 (p.656) row 'Leading to permanent discontinuation —
Leading to permanent discontinuation Any adverse event 76 (8.4) 97 7.6 9 (3.0) 13 3.1
- CagriSema 2.4/2.4 mg · sae · Table 3 (p.656) row 'Serious'; Results, Safety (p.655)
Serious 94 (10.4) 138 10.8 39 (12.9) 51 12.1
Primary sources
- Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-659. PMID: 40544432.
- Novo Nordisk A/S. Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). ClinicalTrials.gov identifier NCT05394519. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05394519
How to cite this page
Medical Adviser's Group. Incretin Atlas: REDEFINE 2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.